01 Increasing Adoption of Ultra-High Barrier Films for Moisture- and Oxygen-Sensitive Drugs The increasing use of moisture- and oxygen-sensitive medicines is driving the adoption of ultra-high barrier pharmaceutical films that provide enhanced product protection and longer shelf life. Packaging manufacturers are developing advanced multi-layer films with superior barrier properties to maintain drug stability throughout storage and distribution. Amcor continues to expand its high-barrier pharmaceutical packaging portfolio with advanced films designed to protect sensitive formulations from moisture and oxygen exposure.
02 Growing Use of Unit-dose Medicines The growing use of unit-dose medicines is encouraging pharmaceutical manufacturers to adopt blister packaging for controlled dosing, product protection, and patient convenience. For instance, TekniPlex Healthcare supplies pharmaceutical blister films and barrier structures for solid-dose medicines, supporting the shift toward unit-dose packaging. As blister packaging expands, the use of high-barrier pharmaceutical films is expected to increase.
01 The high barrier pharmaceutical film market is highly exposed to supply chain disruptions because it depends on globally sourced high-performance polymers, aluminum foil, specialty coatings, adhesives, and pharmaceutical-grade raw materials that must meet stringent regulatory and quality standards. Disruptions in the supply of these critical materials increase production lead times, delay pharmaceutical packaging operations, and raise manufacturing costs, limiting the availability of high barrier films for pharmaceutical packaging worldwide. The market is expected to follow a capacity-constrained recovery, with production and supply improving steadily as raw material availability normalizes, supplier diversification expands, and pharmaceutical packaging manufacturing capacity gradually catches up with growing demand.
01 The high barrier pharmaceutical film market forecasts continued investment and funding activity driven by rising demand for advanced drug packaging, increasing adoption of biologics and moisture-sensitive medicines, and growing emphasis on extended product shelf life.
02 Key Investment and Funding Activities in High Barrier Pharmaceutical Film Market, 2025 Company Funding/Investment (USD) Details Coveris USD 11 Million In August 2025, Coveris completed a USD 11 million investment at its Halle, Germany facility, adding a cast-film extrusion line and upgrading production infrastructure to expand flexible-film capabilities, including recyclable films for thermoforming and medical applications. UFlex Limited USD 33 Million In March 2025, UFlex commissioned an 18,000-MTPA CPP film line in Mexico following an estimated USD 33 million capital expenditure, expanding its regional packaging-film manufacturing capacity.
01 Expansion of Generic Drug & Over-the-Counter Pharmaceutical Production and Increasing Pharmaceutical Manufacturing in Humid Regions Drives Demand The rising production of generic and OTC medicines is increasing the need for packaging that protects formulations during storage while remaining efficient for high-volume manufacturing. This is shifting pharmaceutical producers toward high-barrier films that provide reliable moisture and oxygen protection without adding unnecessary packaging complexity. WHO notes that India supplies about 20% of the global generic medicines market, highlighting the scale of generic production and the resulting packaging requirement.Pharmaceutical production in humid and temperature-variable regions is increasing the need for films that protect medicines from moisture and environmental exposure throughout distribution. This is encouraging manufacturers to use multilayer barrier structures with stronger moisture resistance, particularly for solid-dose products. Amcor’s pharmaceutical blister packaging solutions use high-barrier structures designed to protect sensitive medicines from moisture and oxygen, supporting manufacturers operating across challenging storage and distribution environments.
01 High Production Costs of Multi-Layer High-Barrier Films and Complex Recycling of Film Structures Limit Adoption High production costs restrain the high-barrier pharmaceutical film market because multi-layer structures require several polymers, coatings, or aluminum layers to achieve strong moisture and oxygen protection. These materials and complex converting processes increase manufacturing and quality-control expenses. Higher film costs can raise overall pharmaceutical packaging costs, particularly for price-sensitive generic medicines.Complex recycling of multi-layer barrier films restrains market growth because bonded polymer, coating, and aluminum layers are difficult to separate through conventional recycling processes. Growing sustainability requirements increase pressure on pharmaceutical packaging manufacturers to develop recyclable alternatives without reducing barrier performance. Higher development costs and limited recycling infrastructure can slow the adoption of advanced multi-layer pharmaceutical films.
01 Growing Adoption of Mono-Material High-Barrier Films and Development of PFAS-Free and Halogen-Free Pharmaceutical Barrier Films Create Growth Opportunities The shift toward recyclable mono-material packaging creates opportunities for high-barrier film manufacturers and pharmaceutical packaging suppliers as sustainability requirements increase. The EU’s PPWR is expected to make all packaging on the EU market recyclable in an economically viable way by 2030, supporting future demand for recyclable mono-material barrier structures. As pharmaceutical companies reduce reliance on complex multi-layer laminates, demand for mono-material films that maintain strong moisture and oxygen protection is expected to increase. This creates long-term opportunities for suppliers developing recyclable high-barrier pharmaceutical films.Regulatory and sustainability pressure is encouraging pharmaceutical packaging manufacturers to replace fluorinated and halogen-containing materials with safer barrier structures. This creates opportunities for pharmaceutical film producers and blister-packaging suppliers to develop compliant films without sacrificing moisture and oxygen protection. As regulatory scrutiny increases, adoption of these alternative barrier films is expected to expand across pharmaceutical packaging applications.
01 Microscopic Defects in Multilayer Films and Sealing Restriction Hinders Growth Tiny pinholes, coating gaps, and layer defects can create pathways for moisture and oxygen to enter pharmaceutical packaging, reducing drug stability and shelf life. Detecting these defects requires stringent inspection and quality-control systems, increasing production costs and material rejection rates. High-barrier PCTFE structures are used for highly moisture-sensitive medicines because even small moisture ingress can affect product stability, making defect control critical for manufacturers.Thermoforming and sealing can place mechanical and thermal stress on multilayer films, potentially weakening barrier performance or creating inconsistent seals. The development of kpMax with stable forming and higher machine-output capabilities shows the technical challenge of maintaining barrier performance without sacrificing packaging productivity.
March 2026 Amcor expanded its Lugo di Vicenza, Italy facility with a new production line, quality-control laboratory, and automated warehouse dedicated to high-barrier recycle-ready films.
January 2026 January 2026: Klöckner Pentaplast (kp) highlighted its BarrierXpress supply model for pharmaceutical high-barrier films.